BACKGROUND: Apolipoprotein (apo) M may exert anti-atherogenic properties in experimental studies. Its hepatic gene expression may be linked to glucose and lipid metabolism. Plasma apoM is decreased in obese mouse models. We hypothesized that plasma apoM is lower in metabolic syndrome (MetS) subjects, and determined whether intima media thickness (IMT) is associated with apoM. METHODS: In 19 non-diabetic subjects with and 60 non-diabetic subjects without MetS (NCEP, ATP III criteria), the relationships of plasma apoM with obesity, glucose, insulin, lipids and adipokines, as well as with IMT were determined. RESULTS: Plasma apoM was on average 15% lower in subjects with MetS compared to subjects without MetS (p=0.036). ApoM correlated inversely with body mass index and waist circumference (p<0.001), and positively with total cholesterol, LDL cholesterol and apoA-I (p<0.05). ApoM was not significantly correlated with glucose, insulin, leptin, adiponectin or resistin (p>0.20). Age- and sex adjusted IMT was lower in subjects with MetS (p<0.05), but was unrelated to apoM (p=0.68). In a multiple linear regression model that included the presence of both MetS and apoM, IMT was only related to MetS (p=0.05). CONCLUSIONS: Plasma apoM is reduced in MetS. In this study, apoM did not predict subclinical atherosclerosis.
BACKGROUND: Apolipoprotein (apo) M may exert anti-atherogenic properties in experimental studies. Its hepatic gene expression may be linked to glucose and lipid metabolism. Plasma apoM is decreased in obesemouse models. We hypothesized that plasma apoM is lower in metabolic syndrome (MetS) subjects, and determined whether intima media thickness (IMT) is associated with apoM. METHODS: In 19 non-diabetic subjects with and 60 non-diabetic subjects without MetS (NCEP, ATP III criteria), the relationships of plasma apoM with obesity, glucose, insulin, lipids and adipokines, as well as with IMT were determined. RESULTS: Plasma apoM was on average 15% lower in subjects with MetS compared to subjects without MetS (p=0.036). ApoM correlated inversely with body mass index and waist circumference (p<0.001), and positively with total cholesterol, LDL cholesterol and apoA-I (p<0.05). ApoM was not significantly correlated with glucose, insulin, leptin, adiponectin or resistin (p>0.20). Age- and sex adjusted IMT was lower in subjects with MetS (p<0.05), but was unrelated to apoM (p=0.68). In a multiple linear regression model that included the presence of both MetS and apoM, IMT was only related to MetS (p=0.05). CONCLUSIONS: Plasma apoM is reduced in MetS. In this study, apoM did not predict subclinical atherosclerosis.
Authors: Mingxia Liu; Cecilia Frej; Carl D Langefeld; Jasmin Divers; Donald W Bowden; J Jeffrey Carr; Abraham K Gebre; Jianzhao Xu; Benny Larsson; Björn Dahlbäck; Barry I Freedman; John S Parks Journal: J Lipid Res Date: 2019-05-27 Impact factor: 5.922
Authors: Christina Christoffersen; Marianne Benn; Pernille M Christensen; Philip L S M Gordts; Anton J M Roebroek; Ruth Frikke-Schmidt; Anne Tybjaerg-Hansen; Björn Dahlbäck; Lars B Nielsen Journal: J Lipid Res Date: 2012-07-23 Impact factor: 5.922
Authors: Bas W C Arkensteijn; Jimmy F P Berbée; Patrick C N Rensen; Lars B Nielsen; Christina Christoffersen Journal: Int J Mol Sci Date: 2013-02-25 Impact factor: 5.923
Authors: Lu Zheng; Yuehua Feng; Yuanping Shi; Jun Zhang; Qinfeng Mu; Li Qin; Maria Berggren-Söderlund; Peter Nilsson-Ehle; Xiaoying Zhang; Guanghua Luo; Ning Xu Journal: PLoS One Date: 2014-08-21 Impact factor: 3.240
Authors: Manju Mamtani; Hemant Kulkarni; Thomas D Dyer; Laura Almasy; Michael C Mahaney; Ravindranath Duggirala; Anthony G Comuzzie; Paul B Samollow; John Blangero; Joanne E Curran Journal: BMC Endocr Disord Date: 2014-06-10 Impact factor: 2.763